Boosting COVID-19 vaccination in Latino communities through social networks

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to determine the effectiveness of a social network intervention called REDES in increasing COVID-19 vaccination rates among Latino communities. The study will recruit 300 Latino adults who have received at least one COVID-19 vaccine, dividing them into two groups: one receiving training in motivational interviewing to encourage vaccination among their friends and connections, and the other receiving standard information about the vaccine. Participants will be followed for 18 months to assess vaccination rates and identify barriers and facilitators to vaccine uptake. The findings will help tailor future interventions to improve vaccination rates in similar communities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Eligibility criteria for index participants (eligibility for index participants is intended to select participants who are less vaccine hesitant):

* Age 18 years or older, and
* Self-identifies as Hispanic/Latino, and
* Living in Maryland, and
* Has received at least one COVID-19 vaccine/booster in the last 12 months.

Eligibility criteria for primary and secondary network members (peers):

Eligibility for peers is intended to select for participants who are more vaccine hesitant (e.g. unvaccinated, or have not received at least one COVID-19 vaccine/booster in the last 12 months)

* 18 years old or older, and
* Self-identifies as Hispanic/Latino, and
* Living in Maryland, and
* Provide a study coupon to verify that they were referred by an index or a primary network member, and
* Has not received at least one COVID-19 vaccine/booster in the last 12 months.

Exclusion Criteria:

* Previously participated in the study
* Lacks capacity to consent

Where it's running

• Johns Hopkins University
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Kathleen R Page, MD — Johns Hopkins University
• Study coordinator: Kathleen R Page, MD
• Email: kpage2@jhmi.edu
• Phone: (410) 321-0909

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry

  This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07597876

• MDX2301 in healthy adults and adults at higher risk for severe COVID-19

  This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.

  Recruiting at 2 sites Phase 1 ModeX Therapeutics, An OPKO Health Company · Las Vegas, Nevada and 1 other locations · NCT07445971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.